CSE Bulletin: INDEX – CSE 25 Index Quarterly Rebalancing – Investing News Network

The quarterly rebalancing of the CSE 25 Index will result in the following changes, effective after the close on Friday, June 17, 2022.
Le rééquilibrage trimestriel de l'indice composé du CSE 25 entraînera les modifications suivantes, en vigueur à la fermeture le vendredi 17 juin 2022.
ADDITIONS
 
DELETIONS
 
Deletions from CSE 25 do not necessarily mean a deletion from the Composite.

Les suppressions de CSE 25 ne signifient pas nécessairement une suppression du composite.

For more information about the CSE 25 Index, including the full list of securities and the index methodology, visit the CSE website.
Pour plus d'information sur l'indice composé du CSE 25, incluant la liste complète des titres et la méthodologie indicielle, rendez-vous sur le site Web du CSE.
Contact Information/Coordonnées
Index Management/Gestion de l'indice :
Robert Cook
Senior Vice-President Market Development/Vice-président principal du développement
Robert.Cook@thecse.com (416) 367-7349
Media Relations/Relations avec la presse:
Richard Carleton, CEO
Richard.Carleton@thecse.com (416) 367-7360

News Provided by Newsfile via QuoteMedia

BioHarvest Sciences (CSE:BHSC), a biotechnology innovator, is targeting the international market demand for natural products that provide consumers with functional health and wellness. This includes consumer products ranging from foods enriched with active ingredients like antioxidants to cleaner and more consistent cannabis products. BioHarvest Sciences has developed biofarming, a proprietary breakthrough patented technology, capable of naturally-producing the active ingredients of a plant without having to grow the plant itself. The company has already proven the technology in the rapidly growing nutraceuticals market focusing on dietary supplements and the functional food and beverage ingredients market. Products such as BioHavest Sciences’ VINIA®, which is based on red grapes, has clinically- proven functional benefits, has already positively impacted the lives of thousands of Israelis and is approved for sale in the US.

The global cannabis market is expected to reach US$66.3 billion by the end of 2025, according to a report by Grand View Research. A large portion of the growth has been driven by the adoption of cannabis in the pharmaceutical industry as new products have been developed to treat severe medical conditions such as cancer, Parkinsons, Alzheimers and arthritis. However, issues with consistent cannabis supply can affect the long-term growth of the industry as more countries initiate cannabis programs and legislative reforms, posing potential difficulties for licensed producers to provide enough high-quality products to meet the demand.
BioHarvest Sciences Inc. believes that its biofarming technology is the solution to the cannabis supply and consistency problem. The technology isolates the active ingredient cells from the cannabis plant before multiplying (growing) them in the biofarming process. The technology can do this without using any solvent extraction, genetic modification or synthetic molecular processing techniques. To facilitate its biofarming operation, BioHarvest Sciences Inc. has built a production facility that can produce approximately one ton of active cannabis ingredient powder (equivalent to the cannabis plant dried bud) per year in a 100-square-meter space. The company intends to increase its production to 10 tons per year by 2022.
As of September 2019, the company produced its first cannabis cells in suspension with a cannabinoid profile that was identical to the original cannabis plant without growing the plant. Following a B2B business model, BioHarvest Sciences Inc. intends to sell its active ingredients as a powder for repackaging and formulation to its clients. In addition, the company may License the technology in order to accelerate the industry adoption curve.
In December 2021, the company released the news that it has now grown a significant amount (10kg) of cannabis biomass, all grown in proprietary bioreactors and without growing the plant. Following a B2B business model, BioHarvest Sciences Inc. intends to sell its active ingredients as a powder for repackaging and formulation to its clients. In addition, the company may License the technology in order to accelerate the industry adoption curve.

BioHarvest Sciences has already demonstrated the feasibility and viability of the biofarming technology through its commercially available product called VINIA®. In 2021, BioHarvest recorded US$2.4 million worth of sales orders for VINIA®, a nearly sixfold increase over 2020. The growth is driven by a growing customer base in Israel, and a successful ecommerce launch of VINIA® in the USA. The projected revenue this year is between US$5 million to US7 million, which represents a significant growth of 2.5X-3.5X over 2021.
VINIA® is based on many studies which have demonstrated that moderate consumption of red wine every day is able to have a positive impact on one’s overall heart health as a result of wine’s rich polyphenol content, specifically resveratrol. One 400mg capsule of VINIA® contains the same amount of resveratrol contained in one full bottle of Red Wine without the sugar, calories or alcohol found in red wine. Consumers can currently purchase the powder through the VINIA.com website in a 400-milligram daily dose after BioHarvest made it possible to also make VINIA® available online in the United States, the world's largest market for nutraceutical supplements.
At present, BioHarvest is unstoppable in disrupting industries with unique products and solutions. After VINIA®'s immense sales success, the company has trademarked its proprietary non-GMO biotech platform technology called "Bio-Plant CELLicitation™," replacing "BioFarming".
In an interview, BioHarvest CEO Ilan Sobel talked about Bio-Plant CELLicitation™, a platform technology growing plant cells in industrial-scale bioreactors and eliciting specific molecules to produce unique botanical compounds with high human utility value. Accoridng to Sobel, the unique platform technology allows them to grow full-spectrum, non-GMO cannabis.
""We can play in so many different areas, not just nutraceuticals, not just the cannabinoid space, but in many other areas where we're able to bring the power of the plant to the people," Sobel said.

Dr. Rakib is a serial entrepreneur and seasoned executive. He brings extensive experience in multiple industries. Prior to BioHarvest Sciences, Dr. Rakib co-founded Terayon Communication Systems, led the company from inception as its CEO, and managed its growth from $2M to $380M in revenue. Terayon reached a $7B market capitalization in 2000 and was later on acquired by Motorola. Prior to that, Mr. Rakib was a director of engineering at Cadence design systems which acquired Helios S/W where he served as CTO. Dr. Rakib holds a Ph.D. in Mechanical Engineering and a Ph.D. in Applied Mathematics.
Ilan, brings extensive experience in General Management, International Sales & Marketing, Manufacturing & Operations and leadership expertise in building large-scale businesses and billion- dollar brands. For the past 6 years, Ilan served as COO and transitioned to Chief Commercial Officer of Weissbeerger where he played a major leadership role in building a disruptive BIG Data, IOT & Software Company servicing major Beverage players which was recently purchased by ABInBev. Previously, Ilan served an 18-year stint as an International Employee of The Coca-Cola Company, where he played a pivotal role in key senior leadership positions generating significant revenue and profit growth and improving brand health trends across diverse global markets including the United States, China, South East and West Asia and South Africa.
With a Ph.D in Biotechnology and 20+ years of relevant experience, leading substantial research and development programs in both pharma and biotech, Dr. Hagay has lead the development and implementation of BioHarvest’s technology platform since inception. She previously worked in various leadership positions at BTG corporation which was acquired by FERRING Pharmaceuticals. Dr. Hagay specializes in genetic engineering, molecular biology, tissue culture, monoclonal antibodies and clinical trials. She is the author and co-author of several peer-reviewed – published in scientific papers.
David Ryan has extensive experience in investment and public markets. For the past 20+ years, he has been part of in bringing multiple initial public offerings to market. He has helped raise both equity and debt financings for numerous public companies in both primary and secondary financings as well as served on the board of public companies and in various roles.
Mr. Popper was the co-founder and President of MedReleaf Corp., which was acquired in 2018 for $2.5 billion USD. Prior to its acquisition, MedReleaf was one of the largest and most reputable vertically integrated medical Cannabis producers in the world. Mr. Popper brings over 15 years of international partnerships, entrepreneurial ventures, disruptive industry, large-scale project development, engineering and investment experience. He holds a B.Sc. in Civil Engineering, a M.Sc. in Environmental Fluid Mechanics from Stanford University, and an MBA from the Recanati School of Business.
Dr. Azachi brings 20 years of experience in biochemistry, genetic engineering, tissue culture, molecular biology, and clinical & pre-clinical trials. Prior to BioHarvest, He served as technology Director at HealOr Ltd, a Biopharmaceutical company developing topical therapeutics. Prior, he led product development at the research and development department of Colbar LifeScience, a Johnson & Johnson Company. Dr. Azachi holds a Ph.D in microbiology from the Hebrew University of Jerusalem and a Post-Doc in Molecular Biology of the cell from Weizmann Institute of Science.
Michal Sapir brings 30+ years of experience in the medical device, pharma and biotechnology industries. She has previously served as Senior Director of Project Management at ColBar LifeScience Ltd., a Johnson & Johnson Company. She actively participated in FDA meetings in order to define regulatory pathways, FDA inspections and ISO Audits. She has broad experience in clinical and animal studies; and had formerly served as Affiliate Quality Coordinator & Senior Clinical Research Administrator in Eli Lilly (1995-2000). Michal Holds a Master of Science in Biochemistry.
Brady brings to the advisory board 30 years of experience as an integrative and nutritional medicine practitioner and over 25 years in health sciences academia. He is a licensed naturopathic medical physician in Connecticut and Vermont, is board certified in functional medicine and clinical nutrition, and is a fellow of the American College of Nutrition. Dr. Brady has been the Chief Medical Officer of Designs for Health, Inc. and also currently serves as the Chief Medical Officer for Diagnostic Solutions Labs, LLC. He was the long-time Vice President for health sciences and Director of the Human Nutrition Institute and continues to serve as an associate professor of clinical sciences, at the University of Bridgeport in Connecticut. He has published multiple peer-reviewed scientific papers and textbooks related to chronic pain, autoimmunity, and functional gastroenterology. Furthermore. Dr. Brady appeared on the plenary speaking panels of some of the largest and most prestigious conferences in the field including; IFM, ACAM, A4M, ACN, IHS, AANP, AIHM, and many more.
Mr. Tsur is the co-founder of Kamada Ltd, a public company listed on both the NASDAQ and Tel-Aviv Stock Exchange. He served as its Chief Executive Officer and on its Board of directors since the Company’s inception in 1990. He currently serves as Deputy Chairman of the Board.
He also serves as the Chairman of Kanabo Group Plc, a company listed on the London Stock Exchange, which focuses on distributing Cannabis-derived products for medical patients and non-THC products for CBD consumers.
Steven currently sits on the Board of Directors of two life science companies, one not for profit, and is a member of the University of Maryland's Bioengineering Department Advisory Board. He provides strategy and implementation advice to several organizations on various topics from commercial efforts through operations, business development, product development, portfolio planning to the establishment of international operations. Previously Steve was Head of Biologicals at Cipla Ltd., CEO of Cipla BioTec, President of Glycominds Ltd, EVP of Adamas Pharmaceuticals Inc., CEO of GeneOs Ltd, CEO at DNA Sciences, and was a division President of Monsanto. Steven also worked with McKinsey & Co., and Proctor & Gamble Corporation.
Hadfield brings 40 years of scientific experience to the Canadian-Israeli biotech firm, which has developed and patented a plant bio-cell technology, called BioFarming, capable of growing the active and beneficial plant based ingredients at industrial scale, without the need to grow the plant itself.
INN does not provide investment advice and the information on this profile should not be considered a recommendation to buy or sell any security. INN does not endorse or recommend the business, products, services or securities of any company profiled.
The information contained here is for information purposes only and is not to be construed as an offer or solicitation for the sale or purchase of securities. Readers should conduct their own research for all information publicly available concerning the company. Prior to making any investment decision, it is recommended that readers consult directly with BioHarvest Sciences Inc. and seek advice from a qualified investment advisor.
Move confirms the Company's commitment to bring to market scientific and clinically based therapeutic solutions derived from plants and sets the path for the development of next generation therapeutic solutions including botanical drugs.
BioHarvest Sciences Inc. (CSE: BHSC) ("BioHarvest" or the "Company") has hired Dr. Brian S. Cornblatt as its Chief Medical Officer, marking a significant milestone in the Company's route for the development of next generation therapeutic solutions including botanical drugs.
Dr. Cornblatt has served as Director of Consumer Clinical Research and Science and as Medical Director at Nutramax Laboratories Consumer Care, Inc. In this role Dr. Cornblatt developed novel nutraceutical formulations, designed both in vitro and clinical studies in support of products, and summarized both supporting laboratory and clinical research for healthcare workers and consumers. His most recent development has been a novel line of products (and 18 related clinical trials) which deliver the essential ingredients needed to support the production of sulforaphane, a phytochemical with many emerging indications. Dr. Cornblatt is also the inventor of three issued patents and four pending provisional patents focused on plant-based bioactive compounds and health promotion.
Prior to moving to Nutramax Laboratories in 2010, Dr. Cornblatt was the Scientific Director and Developer of the Catholic Health Initiatives' (CHI) Center for Translational Research (CTR), a combined molecular research laboratory, national biorepository, and diagnostics laboratory. The CTR supported research initiatives throughout CHI's forty Oncology centers.
Cannot view this image? Visit: https://orders.newsfilecorp.com/files/6168/125931_9eab594d94ac6b7c_002full.jpg
Dr. Brian S. Cornblatt
To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/6168/125931_9eab594d94ac6b7c_002full.jpg
Dr. Cornblatt is a Johns Hopkins University School of Medicine Graduate with a Ph.D. in Pharmacology and Molecular Sciences and a postdoctoral fellowship from the Johns Hopkins Bloomberg School of Public Health, Environmental Health Sciences Division of Toxicology.
"We are delighted to welcome Dr. Cornblatt to the leadership team at BioHarvest at a time of transition and growth for us," said BioHarvest CEO Ilan Sobel. "He will help us lead the charge as we take steps to actively expand our line up of clinically based nutraceutical products and move into medicinal prescription products with our polyphenol-based products and Cannabis product line up."
Dr. Cornblatt said "I am excited about the opportunities that BioHarvest has in the medicinal space based on the CELLicitation™ technology. Some of the existing products can already form a potential for future botanical drugs and I am looking at expanding the indications for which unique products like VINIA® can be used. I look forward to working with the capable R&D team to bring to the world unique, clinically based therapeutic solutions."
BioHarvest is seeking to receive authorization in Israel to produce Cannabis for commercial purposes and is also looking to expand production facilities to North America. BioHarvest recently announced that it has produced a meaningful amount (10 kilograms) of full-spectrum Cannabis biomass at a commercial scale without growing the plant itself. (For full illustration, Watch this video or visit https://bioharvest.com. It is the first time that any group – in either industry or academia – has successfully produced meaningful quantities of full-spectrum Cannabis biomass without growing the plant itself. The Cannabis biomass is not genetically modified and was produced using the Company's proprietary BioFarming technology platform, which grows plant cells in their natural structure in proprietary bioreactors. The company has also recently (May 12) unveiled the profile of its unique Cannabis composition. It contains major and minor cannabinoids as well as terpenes.
BioHarvest has a market capitalization of approximately CAD$131M and has raised over CAD$ 58M to date. The Company holds unique patented technology that allows it to produce a unique grade of full spectrum, consistent, and clean Cannabis biomass in industrial-scale bioreactors with manufacturing costs which are significantly below industry benchmarks. Its offering will consist of multiple unique Cannabis compositions selected based on specific indications and B2B customer requirements.
About BioHarvest Sciences Inc.
BioHarvest Sciences Inc. (CSE: BHSC) is a fast-growing Biotech firm listed on the Canadian Securities Exchange. BioHarvest has developed a patented bio-cell growth platform technology capable of growing the active and beneficial ingredients in fruit and plants, at industrial scale, without the need to grow the plant itself. This technology is economical, ensures consistency, and avoids the negative environmental impacts associated with traditional agriculture. BioHarvest is currently focused on nutraceuticals and the medicinal cannabis markets. Visit: www.bioharvest.com.
BioHarvest Sciences Inc.
Ilan Sobel, Chief Executive Officer
For further information, please contact:
Investor Relations
Phone: 778.686.3855
Email: info@bioharvest.com
Forward-Looking Statements
Information set forth in this news release might include forward-looking statements that are based on management's current estimates, beliefs, intentions, and expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. There is no assurance that the Company will be successful in expanding its technology to broader medical applications or conduct clinical trials to validate the efficacy of the Company's products for new forms of medical treatments. There is no assurance that the ability to produce a commercial sized biomass will result in the Company entering into commercial production of Cannabis. Clinical trials are subject to risks of significant cost overruns and lengthy delays with no assurance they will confirm desired results. Even where desired results are obtained government approvals for treatments take considerable time and cannot be guaranteed. There is no assurance that we will achieve our objective of being a leading supplier of Cannabis. Delays and cost overruns may result in delays achieving our objectives. Obtaining market acceptance and regulatory approvals for geographic expansion is subject to risk and cannot be guaranteed. Projected sales of Cannabis will require the company to obtain production and / or export licensing which cannot be assured. There is no assurance the company will successfully expand its lineup of nutraceutical products or move into medical prescription products. Successful completion of these objectives will require additional financing, successful marketing initiatives, and certifications which are subject to uncertainty. In addition, prescription drug products require clinical trials which may be lengthy and expensive and have uncertain results. There is no assurance that the company will be approved for commercial Cannabis production in Israel or elsewhere. Obtaining such approvals is subject to many risks and uncertainties, in addition to the need for financing, including potential delays, unexpected changes in requirements and unexpected failure to meet requirements.
All forward-looking statements are inherently uncertain, and actual results may be affected by a number of material factors beyond our control. Readers should not place undue reliance on forward-looking statements. BHSC does not intend to update forward-looking statement disclosures other than through our regular management discussion and analysis disclosures.
Neither the Canadian Securities Exchange nor its Regulation Services Provider accept responsibility for the adequacy or accuracy of this release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/125931

News Provided by Newsfile via QuoteMedia

BioHarvest Sciences Inc. the (CSE: BHSC) ("BioHarvest" or the "company") today unveiled the composition profile of its full-spectrum Cannabis produced in large-scale industrial bioreactors based on its proprietary Bio-Plant CELLicitation™ platform technology.
On December 8th, 2021, BHSC became the first company ever to announce that it could produce Cannabis biomass without growing the plant itself. The revealing of the unique composition profile of its first product comes as BioHarvest gears up for potential Cannabis commercialization – optimizing the manufacturing process, perfecting measurement techniques, transitioning the 2-ton/year facility to Cannabis and applying for the necessary regulatory approvals.
Reliable testing and measurements demonstrate that the composition profile includes the Cannabinoids THC, CBD, CBG, THCV, CBDV and CBC, as well as the Terpenes Beta-caryophyllene, Beta-panasinsene and Selina. While other minor Cannabinoids are present, their identity determination requires further work on the measurement techniques as the current conventional ones are not advanced enough to deal with such a distinctive Cannabinoids profile. The profile and ratio between the various Cannabinoids found in BioHarvest's product is unique and sets a path for both potential patentability and applicability to address medical indications such as ADHD, pain management and anxiety. For further protection of BioHarvest's IP and to secure patentability, more quantitative information about the profile will be revealed before September 15th, 2022. In the interim, the company confirms with certainty the significance of THC, CBD and CBG quantities inside the unique Cannabis composition.
"These achievements are remarkable and demonstrate the ability to produce unique and consistent Cannabis compositions that would have been impossible using conventional agriculture," said Prof. Zohar Kerem, Head of the Food Chemistry Labs of the Robert H. Smith Faculty of Agriculture, Food and Environment of the Hebrew University of Jerusalem. "I have been closely watching the application of BioHarvest's Bio-Plant CELLicitation™ technology to Cannabis, and I am confident that advanced analysis techniques will become available soon to further unveil the Cannabinoids richness of the unique BioHarvest's compositions."
One of the special characteristics of this Cannabis product is that it is made of trichomes representing 93% of the biomass. Trichomes are the plant's natural "mini-factories" that produce the active Cannabis ingredients (Cannabinoids, terpenes and other phytochemicals). Unlike conventional Cannabis products where a significant part of the biomass includes other parts of the flower which have a bitter taste, BioHarvest's product is primarily composed of trichomes. This significant reduction of bitterness renders the product easier to integrate in food and beverage applications.
Moreover, the unique conformation of our trichomes (amalgamated in a coral shape structure) may provide for enhanced solubility and bio-availability of the product. This would allow administration of lower doses to achieve the same desired effects, which would otherwise require a higher quantity in the case of conventionally cultivated Cannabis products.
"Our consistent, clean and efficacious Cannabis, produced with the highest ESG credentials and capital efficiency, has received a significant boost with the latest conclusive composition profile information," said CEO Ilan Sobel. "This rich full-spectrum combination of Cannabinoids and Terpenes with unique ratios is very promising for addressing medical conditions otherwise treated by synthetic drugs with significant negative side effects. The reduced bitterness taste and the potential improved solubility of our products amount to a game-changer for integration of full-spectrum Cannabis into the food & beverage industry."
BioHarvest plans to bring its first Cannabis products to market in 2022 and will be converting the current VINIA® 2-tons/year facility in Rehovot, Israel to produce Cannabis. This is happening as a result of the transition of all VINIA ® manufacturing to the new 20-ton/year facility in Yavneh, Israel.
About BioHarvest Sciences Inc.
BioHarvest Sciences Inc. (CSE: BHSC) is a fast-growing Biotech firm listed on the Canadian Securities Exchange. BioHarvest has developed a patented bio-cell growth platform technology capable of growing the active and beneficial ingredients in fruit and plants, at industrial scale, without the need to grow the plant itself. This technology is economical, ensures consistency, and avoids the negative environmental impacts associated with traditional agriculture. BioHarvest is currently focused on nutraceuticals and the medicinal cannabis markets. Visit: www.bioharvest.com.
BioHarvest Sciences Inc.
Ilan Sobel, Chief Executive Officer
For further information, please contact:
Dave Ryan, VP Investor Relations & Director
Phone: 1 (604) 622-1186
Email: dave@bioharvest.com
Twitter
Facebook
LinkedIn
YouTube
Forward-Looking Statements
Information set forth in this news release might include forward-looking statements that are based on management's current estimates, beliefs, intentions, and expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. There is no assurance that we will achieve our objective of making our products available in multiple markets. There is no assurance that the Company will be successful in expanding its technology to broader medical applications or conduct clinical trials to validate the efficacy of the Company's products for new forms of medical treatments. Clinical trials are subject to risks of significant cost overruns and lengthy delays with no assurance they will confirm desired results. Even where desired results are obtained government approvals for treatments take considerable time and cannot be guaranteed. There is no assurance the BioFarming technology will make a significant impact on multiple verticals of life -science based businesses in general or in the bio-space industry. There is no assurance that we will achieve our objective of being a leading supplier of Cannabis. Delays and cost overruns may result in delays achieving our objectives obtaining market acceptance and regulatory approvals for geographic expansion is subject to risk and cannot be guaranteed. Projected sales of Cannabis will require the company to obtain production and / or export licensing which cannot be assured. There is no assurance of patentability of the Company's products. Obtaining patents is a lengthy process subject to many uncertainties. The ability of the Company's product to address medical indications in a manner different from other Cannabis products can only be determined after the process of clinical trials, the outcome of which cannot be assured.
In particular there is no assurance the company will obtain a production license or bring its first Cannabis products to market in 2022.
All forward-looking statements are inherently uncertain and actual results may be affected by a number of material factors beyond our control. Readers should not place undue reliance on forward-looking statements. BHSC does not intend to update forward-looking statement disclosures other than through our regular management discussion and analysis disclosures.
Neither the Canadian Securities Exchange nor its Regulation Services Provider accept responsibility for the adequacy or accuracy of this release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/123755

News Provided by Newsfile via QuoteMedia

BioHarvest Sciences Inc. (CSE: BHSC) (OTC:CNVCF) (FSE: 8MV) ("BioHarvest" or the "Company") announced today a financing plan based on a private placement of up to USD $5 Million (approximately $6.3 Million CAD). The funds raised will allow the Company to accelerate the growth plan for its polyphenolsantioxidants and Cannabis verticals.
On March 23, 2021, BHSC announced the completion of the Company's Cannabis R&D program, marking the start of the proposed transition to commercial scale manufacturing. BioHarvest plans to bring its first Cannabis products to market in 2022 and will be converting the current VINIA® 2 tons/year facility in Rehovot, Israel to produce Cannabis. This is happening in conjunction with the transition of all VINIA ® manufacturing to the new 20 tons/year facility in Yavneh, Israel, which will provide the required VINIA ® production capacity to scale VINIA® sales in the US. The transition to Cannabis manufacturing in Israel, combined with the planned incremental marketing spend for VINIA® in the USA, requires additional financing which the Company will seek to raise by issuing up to $5 Million USD of Convertible Notes (the "Notes").
The Notes which will be denominated in Canadian Dollars, will have a term of 24 months, and pay interest of 6% per annum. The Notes will be convertible as to principal and accrued interest , at the option of the holder, at any time following one year from their issuance (the " Anniversary Date') into common shares of the company at a price equal to the closing market price of the Company's common shares on the date of conversion (the "(Closing Price" ) less a discount of 25% if the closing price is $0.50 per share or less and 20% if the closing price is above $0.51 but in any event not less than $0.26 per share (the "Floor Price") and not higher than a ceiling price (the "Ceiling Price") equal to $0.65 if converted within 90 days of the Anniversary Date, $0.75 if converted between 91 and 180 days of the Anniversary Date, $0.85 if converted between 181 and 270 days of the Anniversary Date and $0.95 thereafter.
The Company will have the Option on 30 days notice to redeem all or any part of the Notes for the principal amount outstanding plus accrued interest at any time if either of the following conditions are met:
a) The common shares of the company are listed on a more senior Stock Exchange (the Toronto Stock Exchange, Nasdaq Capital or Global Markets or any market of the New York Stock Exchange.)
b) the Company completes debt or equity financings for gross proceeds in excess of $10 Million USD following the issuance of the Notes.
In the event that the Company issues a Notice of Redemption prior to the Anniversary Date the amount of principal redeemed, and accrued interest on it, will be immediately convertible at the option of the holder.
The company may pay customary commissions or other sales incentives to registered brokers or investment dealers or finders (where permitted by law).
Beside ongoing and customary liabilities to suppliers and employees, currently the Company has no outstanding debt.
Ilan Sobel, CEO, states "Our unprecedented achievements to date in the development and commercialization of our proprietary platform technology presents an opportunity for investors to enjoy the expected success of the Company as it scales its operations for both business verticals. Our leadership in plant cellular biology, our wealth of IP and our operational performance convince us that the current share price of BHSC, which has also been impacted by geopolitical uncertainties, undervalues the Company. By opting for a convertible loan instrument with conversion deferred for one year we avoid dilution at current share price. This USD $5 Million financing gives us the required marketing resources to accelerate the building of ourVINIA® revenue and customer base as well as provide the capital needed to commence Cannabis production in Israel in H2, both of which are major 2022 priorities which will significantly increase the enterprise value."
Q1 2022 Shareholder Update
BioHarvest invites all interested investors and media to our next Shareholders Update, to be held at 11 am PDT, April 7th, 2022. The online meeting will be hosted by CEO Ilan Sobel and will feature a live Q&A session. Free registration to the event is available here: https://app.livestorm.co/st-financial/q1-2022-bioharvest-sciences-shareholder-update?type=detailed.
This news release is provided for information purposes only and it is not an offer for sale or solicitation of an offer to purchase securities of the Company in any United States jurisdiction or any other jurisdiction where prohibited by law. The company's proposed private placement will only be available to qualified investors.
About BioHarvest Sciences Inc.
BioHarvest Sciences Inc. (CSE: BHSC) is a fast-growing Biotech firm listed on the Canadian Securities Exchange. BioHarvest has developed a patented bio-cell growth platform technology capable of growing the active and beneficial ingredients in fruit and plants, at industrial scale, without the need to grow the plant itself. This technology is economical, ensures consistency, and avoids the negative environmental impacts associated with traditional agriculture. BioHarvest is currently focused on nutraceuticals and the medicinal cannabis markets. Visit: www.bioharvest.com.
BioHarvest Sciences Inc.
Ilan Sobel, Chief Executive Officer
For further information, please contact:
Dave Ryan, VP Investor Relations & Director
Phone: 1 (604) 622-1186
Email: dave@bioharvest.com
Twitter
Facebook
LinkedIn
YouTube
Forward-Looking Statements
Information set forth in this news release might include forward-looking statements that are based on management's current estimates, beliefs, intentions, and expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. There is no assurance that we will achieve our objective of making our products available in multiple markets. There is no assurance that the Company will be successful in expanding its technology to broader medical applications or conduct clinical trials to validate the efficacy of the Company's products for new forms of medical treatments. Clinical trials are subject to risks of significant cost overruns and lengthy delays with no assurance they will confirm desired results. Even where desired results are obtained government approvals for treatments take considerable time and cannot be guaranteed. There is no assurance the BioFarming technology will make a significant impact on multiple verticals of life -science based businesses in general or in the bio-space industry. There is no assurance that we will achieve our objective of being a leading supplier of Cannabis. Delays and cost overruns may result in delays achieving our objectives obtaining market acceptance and regulatory approvals for geographic expansion is subject to risk and cannot be guaranteed. Projected sales of Cannabis will require the company to obtain production and / or export licensing which cannot be assured.
In particular there is no assurance the company will obtain a production license or bring its first Cannabis products to market in 2022 or be successful in completing the proposed or subsequent financing or its common shares be listed on a more senior stock exchange.
All forward-looking statements are inherently uncertain and actual results may be affected by a number of material factors beyond our control. Readers should not place undue reliance on forward-looking statements. BHSC does not intend to update forward-looking statement disclosures other than through our regular management discussion and analysis disclosures.
Neither the Canadian Securities Exchange nor its Regulation Services Provider accept responsibility for the adequacy or accuracy of this release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/119622

News Provided by Newsfile via QuoteMedia

BioHarvest Sciences Inc. (CSE: BHSC) (OTC PINK: CNVCF) (FSE:8MV) ("BioHarvest" or "the Company") today announced Q1 2022 sales of its flagship VINIA® product reached USD 787k, representing 112% growth compared to the same quarter of last year.
BioHarvest also had a strong quarter in R&D execution, highlighted by a March 23 declaration of successful completion of its Cannabis R&D program with production of Cannabis biomass in large-scale industrial bioreactors – signaling the start of commercialization of the Cannabis product. BioHarvest is in the process of transitioning the current R&D license to a production license ahead of launching a unique Cannabis composition into the market in H2 2022.
"I am very proud of our Q1 results, which demonstrate another dimension of our capabilities," said CEO Ilan Sobel. "BioHarvest continues to validate its leadership in plant-based bio-technology."
The company managed the total VINIA sales orders in line with production constraints of its existing 2 ton/year facility and accordingly chose to reduce marketing spend in the US in order to avoid out-of-stock occurrences and customer dissatisfaction. The production capacity constraints are being alleviated by a fast transition to a new 20 ton/year facility – a transition which started successfully in March and will positively impact the H2 2022 scale-up of VINIA production and sales. BioHarvest is therefore reiterating its 2022 sales orders guidance of USD 5M -7M representing a 2.5-3.5X growth over 2021.
The careful management of the VINIA® inventory in the US resulted in Q1 sales order in the US (where pilot sales began in May 2021) reaching USD 335k (representing 2% growth over Q4 2021). The Israeli market delivered USD 452k (22% growth over Q1 2021 and a 10% decline from Q4 2022). Sales in Israel were heavily impacted in Q1 by an extraordinary outbreak of the Covid-19 pandemic in January and February, when approximately 25% of the population contracted the virus. March sales in Israel have significantly recovered and April sales so far support BioHarvest's growth trajectories and are in line with the provided guidance.
In early Q3 2022, BioHarvest expects VINIA ® inventory to reach levels that enable significant scaling of the business. US sales metrics in Q1 2022 continue to be very encouraging: VINIA ® has achieved a best-in class verified customer rating of 4.8 out of 5, demonstrating a high level of customer satisfaction, and subscription revenue in Q1 2022 increased 40% compared to Q4 2021.
The second half of the year marketing plan includes the addition of influencer endorsements, customer referral programs and affiliate programs as well as a focused approach addressing key lucrative market segments such as the Christian evangelical market.
"We were able to manage our sales growth despite inventory constraints and keep our overall customer satisfaction intact, and we enjoy fantastic growth prospects given the commencement of manufacturing at our new VINIA production facility," Sobel said. "I am equally excited by the completion of the Cannabis development program and the highly differentiated composition which we will be bringing to the market in H2 2022."
Q1 2022 Shareholder Update
BioHarvest invites all interested investors and media to our next Shareholders Update, to be held at 11 am PDT, April 7th, 2022. The online meeting will be hosted by CEO Ilan Sobel and will feature a live Q&A session. Free registration to the event is available here: https://app.livestorm.co/st-financial/q1-2022-bioharvest-sciences-shareholder-update?type=detailed.
About BioHarvest Sciences Inc.
BioHarvest Sciences Inc. (CSE: BHSC) is a fast-growing Biotech firm listed on the Canadian Securities Exchange. BioHarvest has developed a patented bio-cell growth platform technology capable of growing the active and beneficial ingredients in fruit and plants, at industrial scale, without the need to grow the plant itself. This technology is economical, ensures consistency, and avoids the negative environmental impacts associated with traditional agriculture. BioHarvest is currently focused on nutraceuticals and the medicinal cannabis markets. Visit: www.bioharvest.com.
BioHarvest Sciences Inc.
Ilan Sobel, Chief Executive Officer
For further information, please contact:
Dave Ryan, VP Investor Relations & Director
Phone: 1 (604) 622-1186
Email: dave@bioharvest.com
Twitter
Facebook
LinkedIn
YouTube
Forward-Looking Statements
Information set forth in this news release includes forward-looking statements that are based on management's current estimates, beliefs, intentions, and expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. There is no assurance that strong sales metrics experienced to date will result in future demand or that proposed additional marketing expenditures will result in increased sales. Markets for nutraceuticals are unpredictable and subject to changes in consumer tastes and trends as well as economic factors beyond our control. Delays and cost overruns may result in delays achieving our objectives obtaining market acceptance, and regulatory approvals for geographic expansion is subject to risk and cannot be guaranteed. There is no assurance that the Company sales revenue for 2022 will reach USD 5 to 7 million and there is no assurance that the Company cash flow breaking point will be achieved in 2023. There is no assurance of commercial availability of our Cannabis product in 2022 or that the Company achieves the conversion of the two tons VINIA® facility to Cannabis production in 2022. These things are subject to construction and approval delays and uncertainties that may be beyond the control of BioHarvest. Projected sales of Cannabis will require the Company to obtain production and/or export licensing which cannot be assured.
All forward-looking statements are inherently uncertain and actual results may be affected by a number of material factors beyond our control. Readers should not place undue reliance on forward-looking statements. BHSC does not intend to update forward-looking statement disclosures other than through our regular management discussion and analysis disclosures.
Readers are cautioned that sales growth and revenue alone do not give an accurate picture of the financial position of the Company and should be read in the context of the Company's annual and quarterly financial statements.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/119445

News Provided by Newsfile via QuoteMedia

BioHarvest Sciences Inc. (CSE: BHSC) ("BioHarvest" or the "Company") today announced that it has produced Cannabis Biomass in large scale industrial bioreactors, which represents the completion of the Company's Cannabis R&D program.
On December 8th, 2021, BHSC became the first company ever to announce that it could produce Cannabis biomass without growing the plant itself. Building on that breakthrough, the Company has made significant progress, and has now produced Cannabis in large scale industrial bioreactors, marking the start of the transition to commercial scale manufacturing. To that end, the Company has commenced the process to obtain a production license in Israel for its Cannabis products to complement the R&D license it has used to date for the Cannabis development program.
Dr. Yochi Hagay, CTO, said "I am elated and proud of this achievement. The R&D team has relentlessly pursued this moment, which marks a new era for the Cannabis industry. Our proprietary and unique amalgamated trichome structure has proven resistant to shear forces applied during the cell growth process in liquid media and it will demonstrate more advantages when it comes to the medicinal application of our products. I have never doubted our ability to use our CELLicitation technology to produce Cannabis without the need to grow the plant itself and we have broken biological barriers to grow high performance trichomes in liquid suspension. We are now ready to bring our first unique Cannabis compositions to the world. We will of course continue to invest in Cannabis R&D to add more Cannabis products to the portfolio, appreciate the IP assets and drive even further manufacturing efficiencies."
BioHarvest plans to bring its first Cannabis products to market in 2022 and will be converting the current VINIA® 2 tons/year facility in Rehovot, Israel to produce Cannabis. This is happening in conjunction with the transition of all VINIA ® manufacturing to the new 20 tons/year facility in Yavneh, Israel, which will support the scaling of successful sales of VINIA® in the US and beyond.
Ilan Sobel, CEO, states "Our unprecedented achievements present a great opportunity for the Cannabis industry. Consistent, clean, and efficacious Cannabis that is produced with the highest ESG credentials and capital efficiency with significantly lower manufacturing costs is the revolution this industry needs to gain further market traction and trust by the regulators worldwide. Our CELLicitation platform technology is a true market disruptor, cementing BioHarvest's position as a leader in plant cellular biology. With the completion of the initial Cannabis R&D program, more focus can now be applied towards achieving the desired scale for our two business verticals, Polyphenols/Antioxidants and Cannabis."
About BioHarvest Sciences Inc.
BioHarvest Sciences Inc. (CSE: BHSC) is a fast-growing Biotech firm listed on the Canadian Securities Exchange. BioHarvest has developed a patented bio-cell growth platform technology capable of growing the active and beneficial ingredients in fruit and plants, at industrial scale, without the need to grow the plant itself. This technology is economical, ensures consistency, and avoids the negative environmental impacts associated with traditional agriculture. BioHarvest is currently focused on nutraceuticals and the medicinal cannabis markets. Visit: www.bioharvest.com.
BioHarvest Sciences Inc.
Ilan Sobel, Chief Executive Officer
For further information, please contact:
Dave Ryan, VP Investor Relations & Director
Phone: 1 (604) 622-1186
Email: dave@bioharvest.com
Twitter
Facebook
LinkedIn
YouTube
Forward-Looking Statements
Information set forth in this news release might include forward-looking statements that are based on management's current estimates, beliefs, intentions, and expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. There is no assurance that we will achieve our objective of making our products available in multiple markets. There is no assurance that the Company will be successful in expanding its technology to broader medical applications or conduct clinical trials to validate the efficacy of the Company's products for new forms of medical treatments. Clinical trials are subject to risks of significant cost overruns and lengthy delays with no assurance they will confirm desired results. Even where desired results are obtained government approvals for treatments take considerable time and cannot be guaranteed. There is no assurance the BioFarming technology will make a significant impact on multiple verticals of life -science based businesses in general or in the bio-space industry. There is no assurance that we will achieve our objective of being a leading supplier of Cannabis. Delays and cost overruns may result in delays achieving our objectives obtaining market acceptance and regulatory approvals for geographic expansion is subject to risk and cannot be guaranteed. Projected sales of Cannabis will require the company to obtain production and / or export licensing which cannot be assured.
In particular there is no assurance the company will obtain a production license or bring its first Cannabis products to market in 2022.
All forward-looking statements are inherently uncertain and actual results may be affected by a number of material factors beyond our control. Readers should not place undue reliance on forward-looking statements. BHSC does not intend to update forward-looking statement disclosures other than through our regular management discussion and analysis disclosures.
Neither the Canadian Securities Exchange nor its Regulation Services Provider accept responsibility for the adequacy or accuracy of this release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/117749

News Provided by Newsfile via QuoteMedia

The Gummy Project (CSE: GUMY) (FSE: 0OS) (OTCQB: POTVF) ("GUMY" or the "Company"). On Tuesday, June 14, 2022, OTC Markets informed the Company that it became aware of certain promotional activities concerning the Company and its common stock traded on the OTCQB Marketplace, specifically the distribution of promotional emails on June 8, 2022 and June 14, 2022, by an unaffiliated third-party that contained certain charting and technical analysis as well as recent business milestones which were previously publicly disclosed by the Company. The promotional materials did not have a material impact on the Company's common share price. After inquiry, the Company determined that the third party, which was not engaged by the Company or any of its officers, directors, controlling shareholders or any third-party service providers, distributed the promotional emails. The Company had no editorial oversight of the promotional material nor any opportunity to review in advance of the distribution; however, the Company has subsequently reviewed the specific details related to the Company that were included in such promotional emails and has confirmed the factual details included therein are not materially false andor misleading. The Company cautions readers that the opinions made in the promotional materials are speculative in nature. For more complete and specific information regarding the Company, its prospects and the risks associated with those prospects, readers should review the Company's Listing Statement dated as of May 26, 2022 and other public filings on SEDAR, its website and other reliable sources. The Company encourages investors to contact their investment advisors prior to making any investment.
Further, the Company understands this promotional activity coincided with increased trading activity in the Company's common shares beginning on or about June 8, 2022 The Company does not believe the promotional activities were a factor in the recent increase in trading volume of the Company's common shares. Instead, the Company attributes the increased trading volume to currently heightened investor interest as a result of its recent press releases which disclosed that the Company has completed its initial production and secured sales partnerships with the "Bard on the Beach Shakespeare Festival" as well as Flair Airlines.
After an inquiry by management, none of the Company's executive officers, directors or, to the knowledge of the Company, any controlling shareholders or third-party service providers sold or purchased common shares of the Company within the past 90 days.
In the last twelve months, the Company has engaged Investing News Network (as previously disclosed in a press release dated February 16, 2022), Stockwatch, and World of Vegan (as previously disclosed in a press release dated March 17, 2022) for marketing services.
OTC Markets has further requested that the Company state whether it has issued any shares or convertible instruments allowing conversion to equity securities at prices constituting a discount to the current market rate at the time of the issuance. As disclosed in its public filings on SEDAR, the Company has from time to time issued shares or convertible instruments allowing conversion to equity securities at prices constituting a discount to the current market rate at the time of the issuance in accordance with the policies of the Canadian Securities Exchange. Please refer to the Company's Listing Statement (Form 2A) dated May 26, 2022, which is filed under the Company's profile on SEDAR, for a full list of such share issuances.
About The Gummy Project
We are a growing community of individuals and organizations who believe small contributions can add up to something big. We sell low sugar, plant based gummy products while raising money (and awareness) to support endangered keystone species. We are the only "better for you" candy company that is built to support our planet's most precious species and ecosystems, while educating our future generations on the steps we must take today, to ensure a viable tomorrow.
Charlie Lamb, President & CEO, Director
Telephone: 1(236) 317-2812 – Toll free 1(888) 556-9656
E-mail: investors@shopgummies.com
Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward Looking Statements
Certain information set forth in this news release may contain forward-looking statements that involve substantial known and unknown risks and uncertainties. All statements other than statements of historical fact are forward-looking statements, including, without limitation, statements regarding future financial position, business strategy, use of proceeds, corporate vision, proposed acquisitions, partnerships, joint-ventures and strategic alliances and co-operations, budgets, cost and plans and objectives of or involving the Company. Such forward-looking information reflects management's current beliefs and is based on information currently available to management. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "expects", "is expected", "budget", "scheduled", "estimates", "forecasts", "predicts", "intends", "targets", "aims", "anticipates", "may" or "believes" or variations (including negative variations) of such words and phrases or may be identified by statements to the effect that certain actions "may", "could", "should", "would", "might" or "will" be taken, occur or be achieved. A number of known and unknown risks, uncertainties and other factors may cause the actual results or performance to materially differ from any future results or performance expressed or implied by the forward-looking information. These forward-looking statements are subject to numerous risks and uncertainties, certain of which are beyond the control of the Company including, but not limited to, the impact of general economic conditions, industry conditions, risks relating to epidemics or pandemics such as COVID-19, including the impact of COVID-19 on the Company's business, financial condition, and results of operations. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. The Company does not assume any obligation to update or revise its forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by securities laws.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/128114

News Provided by Newsfile via QuoteMedia

Investing in the biotech industry can be a long road to gains given the sector’s volatility.
Even with a good understanding of the system, no one can predict which treatment, device or therapy will give the biggest return, making biotech exchange-traded funds (ETFs) a more secure option than individual biotech stocks.
An ETF is a relatively safe investment route that can minimize losses while offering exposure to multiple companies instead of focusing on the gains and losses of a single biotech stock.
With that in mind, here’s a brief look at the five top biotechnology ETFs by total assets. Data was sourced from ETFdb.com on May 27, 2022, and all data was current as of that time.
Total assets: US$7.37 billion
The iShares NASDAQ Biotechnology ETF was launched on February 5, 2001, and tracks 377 holdings. This iShares ETF is a diversified fund in that it provides exposure to biotechnology, pharmaceutical and life science tools and services. Its overarching investment goal is to track NASDAQ-listed companies focused on these areas.
Its top three holdings are: Amgen (NASDAQ:AMGN), weighted at 9.84 percent; Gilead Sciences (NASDAQ:GILD) with a 8.58 percent weight; and Regeneron Pharmaceuticals (NASDAQ:REGN) at a weight of 7.55 percent.
Total assets: US$5.54 billion
Established on February 6, 2006, the SPDR S&P Biotech ETF is a largely equally weighted fund that focuses mostly on biotech companies with some pharmaceutical companies. As noted by ETF.com, it focuses on small- and micro-cap companies, which makes the weight of each holding smaller than the holdings of other ETFs in this sector.
The SPDR S&P Biotech ETF has 158 companies in its portfolio, with the top three being: Halozyne Therapeutics (NASDAQ:HALO), which has a 1.52 percent weighting; United Therapeutics (NASDAQ:UTHR), weighted at 1.51 percent; and Biohaven Pharmaceutical Holding Company (NYSE:BHVN), with a 1.38 percent weight.
Total assets: US$2.44 billion
The ARK Genomic Revolution Multi-Sector ETF came into existence on October 31, 2014, and tracks 48 holdings. This ETF has a specific industry area of focus and follows companies that develop products such as: CRISPR technology, bioinformatics, molecular diagnostics and stem cells.
This top biotechnology ETF's three most significant company holdings are: Exact Sciences (NASDAQ:EXAS), weighted at 8.9 percent; Ionis Pharmaceuticals (NASDAQ:IONS) at a weight of 7.48 percent; and Teledoc Health (NYSE:TDOC) at 5.35 percent.
Total assets: US$1.26 billion
The First Trust Amex Biotechnology Index entered the market on June 23, 2006, and aims to track the NYSE Arca Biotechnology Index as closely as it can. Companies in this fund are generally involved in areas such as recombinant DNA technology, molecular biology, genetic engineering and genomics.
The fund has only 31 holdings; this means they are largely equally weighted. The top three holdings of the fund are the following large-cap companies: Grifols (NASDAQ:GRFS) at a 4.69 percent weighting; United Therapeutics, representing a 4.47 percent weight; and Gilead Sciences, coming in at a 3.98 percent weight.
Total assets: US$608.86 million
Founded on May 28, 2015, the Direxion Daily S&P Biotech Bull 3x Shares ETF does not mirror an index. Instead, its goal is to obtain daily investment results of at least 300 percent of the S&P Biotechnology Select Industry Index.
Like some of the other ETFs on this list, companies in the Direxion Daily S&P Biotech Bull 3x Shares ETF have an equally weighted average. Its top holdings include: Halozyme Therapeutics, which has a 0.88 percent weight; United Therapeutics with a weight of 0.85 percent; and Alkermes (NASDAQ:ALKS) at a weight of 0.79 percent.
This is an updated version of an article first published by the Investing News Network in 2016.

Don’t forget to follow us @INN_LifeScience for real-time news updates!
Securities Disclosure: I, Melissa Pistilli, hold no direct investment interest in any company mentioned in this article.
Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of fifty-four cents ($0.54) per share on the $.10 par value common stock of the company. The dividend is payable on August 1, 2022 to stockholders of record at the close of business on July 1, 2022.
In addition, the Board of Directors has declared a quarterly dividend of fifty cents ($0.50) per share on the company's $2.00 convertible preferred stock, payable September 1, 2022, to stockholders of record at the close of business on August 9, 2022.
About Bristol Myers Squibb Company
Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn , Twitter , YouTube , Facebook , and Instagram .
corporatefinancial-news

View source version on businesswire.com: https://www.businesswire.com/news/home/20220615006041/en/
Media:
media@bms.com

Investors:
investor.relations@bms.com
News Provided by Business Wire via QuoteMedia

Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has elected Deepak L. Bhatt, M.D., MPH., to the Board, effective June 14, 2022. Dr. Bhatt will serve as a member of the Science & Technology Committee of the Board of Directors.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220615006039/en/
Deepak L. Bhatt, M.D., M.P.H (Photo: Business Wire)
"We are pleased to welcome Dr. Deepak L. Bhatt to our Board of Directors," said Giovanni Caforio , M.D., board chair and chief executive officer, Bristol Myers Squibb. "Through his role as a physician and leading researcher in cardiovascular medicine, Deepak's insight and expertise will be beneficial as we continue to progress our long-term strategy, transform our pipeline and bring best-in-class medicines that benefit patients with serious unmet diseases."
Dr. Bhatt is currently the executive director of interventional cardiovascular programs at Brigham and Women's Hospital. He brings to the Board more than 20 years of research experience in acute coronary syndromes, preventive cardiology, and advanced techniques in cardiac, cerebral, and peripheral intervention. He has served as the principal or co-principal investigator for cardiovascular clinical trials focused on interventional cardiology, anti-thrombotic therapy, lipid-lowering therapy, heart failure, obesity, and diabetes, among other areas.
Prior to his current position, Dr. Bhatt served as chief of cardiology at VA Boston Healthcare from 2008-2013. During 2001-2008, Dr. Bhatt held a number of roles of increasing responsibility at the Cleveland Clinic in Cleveland, Ohio. In addition to being an attending physician, he served as an associate director of the Cleveland Clinic Cardiovascular Coordinating Center, director of the interventional cardiology fellowship, as well as the associate director of the cardiovascular medicine fellowship.
He received his medical degree from Cornell University and a masters in public health from the Harvard School of Public Health. He completed his internship and residency training in internal medicine at the Hospital of the University of Pennsylvania, and was a fellow in interventional cardiology and cerebral and peripheral vascular intervention at the Cleveland Clinic. Dr. Bhatt received his undergraduate degree, a bachelor of science, from the Massachusetts Institute of Technology.
Theodore R. Samuels , the Board's lead independent director said, "Deepak is an accomplished physician who has led major advances in the treatment of cardiovascular disease and his significant scientific insights will be an asset to our company. The additional clinical expertise will prove valuable as we progress our pipeline and help ensure that our patients and shareholders continue to benefit from diverse experiences and perspectives on our board."
Dr. Bhatt commented, "As a recognized leader in the development of transformational medicines, including for cardiovascular disease, Bristol Myers Squibb continues to innovate and develop first-in-class medicines that have the potential to benefit patients with serious unmet needs. It is an honor to join the Board, and I look forward to working alongside with my fellow directors to help build upon the company's legacy of innovation to the benefit of more patients around the world."
With the appointment of Dr. Bhatt, effective June 14, 2022, the size of the Board will increase to 11. He will receive compensation in accordance with the company's director compensation program. For more information about the Bristol Myers Squibb Board of Directors, click here .
About Bristol Myers Squibb
Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn , Twitter , YouTube , Facebook , and Instagram .
Corporatefinancial-news

View source version on businesswire.com: https://www.businesswire.com/news/home/20220615006039/en/
Bristol Myers Squibb
Media:
media@bms.com
Investor Relations:
investors@bms.cominvestor.relations @bms.com
News Provided by Business Wire via QuoteMedia

The Gummy Project Inc. (CSE: GUMY) (OTCQB: POTVF) has meticulously navigated its way into the booming global Gummy Market with "better for you" low sugar, plant-based, gluten-free gummy products and a purpose-driven approach. By tapping into the public's desire for "better for you" candy options while also supporting the planet's endangered species, the company's Chief Executive Officer ("CEO"), Charlie Lamb, and his team have set out to establish their own footprint in the industry-one gummy at a time.
Entering the global gummy market certainly makes sense given the market was valued at $17.8 billion in 2021, and according to a report by Grand View Research, is expected to balloon to a more than $42-billion market by 2028 and expanding at a CAGR of 12.6% over the forecast period.
Developing a footprint in the industry starts with brand awareness, and that process starts with product, so last week, The Gummy Project ("Gummy Project") announced a significant milestone in advancing the company's strategic business plan on its path to launching the company's brand across Canada and eventually into the United States. Gummy Project has now finished the first production run of the company's initial gummy products-Watermelon Sharks and Peachy Bees.
During production, the company generated 80,000, 50-gram bags, (40,000 bags per product), which are expected to be ready for retail distribution starting this week, and 8,500 snack-sized packages (10 grams) of each product, which are slated to be ready for distribution next week.
When discussing what prompted the CEO to transition into the gummy market, Charlie Lamb said, "Over the last few years, we have observed the quick creation and rapid growth of the low-sugar gummy market. First, we set out to enter this market with a better tasting product than what is currently available, and second, develop a purpose-driven brand that is truly different than what we see in the market today."
This week's announcement that Gummy Project entered into a partnership to become the exclusive supplier of gummy products for Flair Airlines is a strong signal that the company is, in fact, developing a better tasting, "better for you" gummy, developing brand awareness and the company's products are being recognized and accepted by industries that can quickly broaden Gummy Project's reach.
And to fulfill its purpose-driven strategy, as each new animal shaped gummy is created, Gummy Project partners with a carefully selected organization that is focused on saving that same animal to support the global effort and raise awareness to protect endangered "Keystone Species" that are crucial to the planet's ecosystems. To that end, Gummy Project will give a portion of the proceeds from each bag of gummies sold to the corresponding organization.
Bee and Shark gummies will lead the way for Gummy Project's consumer launch and help build the company's purpose-driven conservation partnerships. The first two organizations that have partnered with Gummy Project are "The Bee Conservancy," an organization protecting bees and the environments that sustain them to ensure ecological health and security for all, and "OCEARCH," a global non-profit organization conducting unprecedented research on shark populations in order to accelerate the ocean's return to balance and abundance.
Gummy Project's CEO explained the importance of developing these partnerships, "In our opinion, every company has a responsibility to do something good in this world. We chose to support endangered keystone species because losing these species will have a significant impact on key ecosystems and the overall health of our planet. So, while Elon Musk is working to get us set up on Mars, we are working to ensure a viable future for humanity-here on this beautiful planet we call Earth."
Gummy Project knows that in order to set itself apart from competitors in the industry, the taste of its gummies is vitally important. And the company's thoughtful process in choosing its flavor profiles could be exactly what drives sales over other brands. Charlie Lamb's team engaged in a thorough process that included three rounds of research to arrive at the flavors they used to develop its first two gummy products.
First, they convened a focus group to conduct research on what flavors consumers prefer-more common flavors or some newer, off-the-beaten-path flavors. They chose to see some new and interesting flavors. Then, the company offered the focus group a list of obscure flavors to choose from, and the research group landed on watermelon and peach for the company's first two products. With the flavors chosen, it was now on to the third round of research-taste tests on the street with total strangers. The company used several rounds of taste tests to fine tune the flavor formulation until Gummy Project received almost unanimous positive feedback on both flavors.
Gummy Project was recently invited to participate in the widely popular Sweets and Snacks Expo in Chicago, so what better audience to introduce the company's new products. When asked what the reaction from the industry and from those who purchase goods in the industry was, Charlie Lamb said, "The response we have received from individual consumers to potential retailers has been incredibly positive. We have consistently heard that our product tastes better than any of the other low-sugar gummies in the market today. And people absolutely love our brand, our packaging, our purpose, and our story. So much so that we were selected as one of the two most innovative new companies at the 2022 Sweets and Snacks Expo where we got the chance to present on the innovation stage and received overwhelmingly positive feedback."
These are exciting times at Gummy Project as the company's strategic business plan is right on schedule. With the first two products chosen, purpose-driven partnerships in place, flavors perfected, and the initial production run complete, now the company turns to distribution. Gummy Project's CEO stated that the company has a multi-tiered sales channel approach that should see the company pick up significant brand awareness early while enabling Gummy Project to test different channels simultaneously, and then choose the winners and where to invest more heavily.
"This includes our initial launch in Canada by July 2022 where we will have an e-commerce site shipping Canada-wide; where we'll be listed on various online marketplaces as an 'add to cart' product; and where we'll be getting our gummies into physical retail stores throughout Vancouver to start (as a test market) through our distribution partner, Deans Dairy & Specialty Foods," said Charlie Lamb.
He added, "By September/October 2022, we plan to launch in the United States with a similar set of sales channels, focusing heavily on physical retail."
And as Gummy Project grows, Charlie Lamb has a strategy that could see the brand eventually become a household name, "Our go-to-market strategy also includes a focus on airlines and major hotel chains. Over time, we may consider sports teams/arenas and other venues where a somewhat captive audience can have the time and space to see our product and to learn about our product and our purpose (aside from the regular grocery shopping routine)."
With exponential growth expected in the gummy market over the next 6 years, it's clear that consumers love gummies. But Gummy Project also realizes that consumers are collectively looking for healthier alternatives in all categories. And according to Charlie Lamb, "This makes the exploding low-sugar gummy market an inevitability, and we believe that we are getting into this market at the exact right time where other brands have paved the way by creating adequate shelf space in major retail. This provides the opportunity for us to enter the market with something different, present our brand and win that shelf space."
To learn more about The Gummy Project Inc. visit https://shopgummies.com
About The Gummy Project
The Gummy Project is a growing community of individuals and organizations who believe small contributions can add up to something big. The company sells low-sugar, plant-based gummy products while raising money (and awareness) to support endangered keystone species. Gummy Project is the only "better for you" candy company that is built to support our planet's most precious species and ecosystems, while educating our future generations on the steps we must take today, to ensure a viable tomorrow.
About Stock Market Media Group
Stock Market Media Group is a news and media content development IR/PR firm offering a platform for corporate stories to unfold in the media with feature news articles, press releases, research reports, corporate videos, and radio-style CEO interviews. Your story, our words!
This article was written based on publicly available information. Stock Market Media Group may, from time to time, include our own opinions about the companies, their business, markets and opportunities in our articles. Any opinions we may offer about any of the companies we write about are solely our own and are made in reliance upon our rights under the First Amendment to the U.S. Constitution and are provided solely for the general opinionated discussion of our readers. Our opinions should not be considered to be complete, precise, accurate, or current investment advice, or construed or interpreted as research. Any investment decisions you may make concerning any of the securities we write about are solely your responsibility based on your own due diligence. Our publications are provided only as an informational aid, and as a starting point for doing additional independent research. We encourage you to invest carefully and read the investor information available at the web site of the U.S. Securities and Exchange Commission at www.sec.gov, where you can also find The Gummy Project's filings and disclosures. We also recommend, as a general rule, that before investing in any securities, you consult with a professional financial planner or advisor, and you should conduct a complete and independent investigation before investing in any security after prudent consideration of all pertinent risks. We are not a registered broker, dealer, analyst, or advisor. We hold no investment licenses and may not sell, offer to sell, or offer to buy any security. Our publications about The Gummy Project are not a recommendation to buy or sell a security.
Should Stock Market Media Group and its management own shares in the profiled company, they may benefit from any increase in the share price of the profiled companies and hold the right to sell the shares bought at any given time including shortly after the release of the company's profile. Section 17(b) of the 1933 Securities and Exchange Act requires publishers who distribute information about publicly traded securities for compensation, to disclose who paid them, the amount, and the type of payment. Under the Securities Act of 1933, Section 17(b), Stock Market Media Group discloses that it was remunerated one-thousand, three hundred dollars paid for by a third party via bank wire, to produce this content related to The Gummy Project.
Stock Market Media Group and its management do not own any shares in The Gummy Project and never accepts compensation in free-trading shares for its marketing services of the company being profiled, however third parties that have compensated Stock Market Media Group may hold free-trading shares of the company being profiled and could very well be selling, holding or buying shares of the company's stock at the same time the content is being disseminated to potential investors; this should be viewed as a definite conflict of interest and as such, the reader should take this into consideration.
If Stock Market Media Group ever accepts compensation in the form of free trading shares of the company being profiled and decides to sell these shares into the public market at any time before, during, or after the release of the company's profile, our disclaimer will be updated accordingly to reflect the current position of any free trading shares received as compensation for our services.
Click here to connect with The Gummy Project Inc. (CSE: GUMY) (OTCQB: POTVF) to receive an Investor Presentation
Source
The Gummy Project Inc. ( CSE: GUMY ) ( OTCQB: POTVF ) has meticulously navigated its way into the booming global Gummy Market with "better for you" low sugar, plant-based, gluten-free gummy products and a purpose-driven approach.  By tapping into the public's desire for "better for you" candy options while also supporting the planet's endangered species, the company's Chief Executive Officer ("CEO"), Charlie Lamb, and his team have set out to establish their own footprint in the industry—one gummy at a time.
Entering the global gummy market certainly makes sense given the market was valued at $17.8 billion in 2021, and according to a report by Grand View Research, is expected to balloon to a more than $42-billion market by 2028 and expanding at a CAGR of 12.6% over the forecast period.
Developing a footprint in the industry starts with brand awareness, and that process starts with product, so last week, The Gummy Project ("Gummy Project") announced a significant milestone in advancing the company's strategic business plan on its path to launching the company's brand across Canada and eventually into the United States.  Gummy Project has now finished the first production run of the company's initial gummy products—Watermelon Sharks and Peachy Bees.
During production, the company generated 80,000, 50-gram bags, (40,000 bags per product), which are expected to be ready for retail distribution starting this week, and 8,500 snack-sized packages (10 grams) of each product, which are slated to be ready for distribution next week.
When discussing what prompted the CEO to transition into the gummy market, Charlie Lamb said, "Over the last few years, we have observed the quick creation and rapid growth of the low-sugar gummy market. First, we set out to enter this market with a better tasting product than what is currently available, and second, develop a purpose-driven brand that is truly different than what we see in the market today."
This week's announcement that Gummy Project entered into a partnership to become the exclusive supplier of gummy products for Flair Airlines is a strong signal that the company is, in fact, developing a better tasting, "better for you" gummy, developing brand awareness and the company's products are being recognized and accepted by industries that can quickly broaden Gummy Project's reach.
And to fulfill its purpose-driven strategy, as each new animal shaped gummy is created, Gummy Project partners with a carefully selected organization that is focused on saving that same animal to support the global effort and raise awareness to protect endangered "Keystone Species" that are crucial to the planet's ecosystems.  To that end, Gummy Project will give a portion of the proceeds from each bag of gummies sold to the corresponding organization.
Bee and Shark gummies will lead the way for Gummy Project's consumer launch and help build the company's purpose-driven conservation partnerships.  The first two organizations that have partnered with Gummy Project are "The Bee Conservancy," an organization protecting bees and the environments that sustain them to ensure ecological health and security for all, and "OCEARCH," a global non-profit organization conducting unprecedented research on shark populations in order to accelerate the ocean's return to balance and abundance.
Gummy Project's CEO explained the importance of developing these partnerships, "In our opinion, every company has a responsibility to do something good in this world.  We chose to support endangered keystone species because losing these species will have a significant impact on key ecosystems and the overall health of our planet. So, while Elon Musk is working to get us set up on Mars, we are working to ensure a viable future for humanity—here on this beautiful planet we call Earth."
Gummy Project knows that in order to set itself apart from competitors in the industry, the taste of its gummies is vitally important.  And the company's thoughtful process in choosing its flavor profiles could be exactly what drives sales over other brands.  Charlie Lamb's team engaged in a thorough process that included three rounds of research to arrive at the flavors they used to develop its first two gummy products.
First, they convened a focus group to conduct research on what flavors consumers prefer—more common flavors or some newer, off-the-beaten-path flavors.  They chose to see some new and interesting flavors.  Then, the company offered the focus group a list of obscure flavors to choose from, and the research group landed on watermelon and peach for the company's first two products.  With the flavors chosen, it was now on to the third round of research—taste tests on the street with total strangers.  The company used several rounds of taste tests to fine tune the flavor formulation until Gummy Project received almost unanimous positive feedback on both flavors.
Gummy Project was recently invited to participate in the widely popular Sweets and Snacks Expo in Chicago, so what better audience to introduce the company's new products.  When asked what the reaction from the industry and from those who purchase goods in the industry was, Charlie Lamb said, "The response we have received from individual consumers to potential retailers has been incredibly positive.  We have consistently heard that our product tastes better than any of the other low-sugar gummies in the market today.  And people absolutely love our brand, our packaging, our purpose, and our story.  So much so that we were selected as one of the two most innovative new companies at the 2022 Sweets and Snacks Expo where we got the chance to present on the innovation stage and received overwhelmingly positive feedback."
These are exciting times at Gummy Project as the company's strategic business plan is right on schedule.  With the first two products chosen, purpose-driven partnerships in place, flavors perfected, and the initial production run complete, now the company turns to distribution.  Gummy Project's CEO stated that the company has a multi-tiered sales channel approach that should see the company pick up significant brand awareness early while enabling Gummy Project to test different channels simultaneously, and then choose the winners and where to invest more heavily.
"This includes our initial launch in Canada by July 2022 where we will have an e-commerce site shipping Canada-wide; where we'll be listed on various online marketplaces as an ‘add to cart' product; and where we'll be getting our gummies into physical retail stores throughout Vancouver to start (as a test market) through our distribution partner, Deans Dairy & Specialty Foods," said Charlie Lamb.
He added, "By September/October 2022, we plan to launch in the United States with a similar set of sales channels, focusing heavily on physical retail."
And as Gummy Project grows, Charlie Lamb has a strategy that could see the brand eventually become a household name, "Our go-to-market strategy also includes a focus on airlines and major hotel chains.  Over time, we may consider sports teams/arenas and other venues where a somewhat captive audience can have the time and space to see our product and to learn about our product and our purpose (aside from the regular grocery shopping routine)."
With exponential growth expected in the gummy market over the next 6 years, it's clear that consumers love gummies.  But Gummy Project also realizes that consumers are collectively looking for healthier alternatives in all categories.  And according to Charlie Lamb, "This makes the exploding low-sugar gummy market an inevitability, and we believe that we are getting into this market at the exact right time where other brands have paved the way by creating adequate shelf space in major retail.  This provides the opportunity for us to enter the market with something different, present our brand and win that shelf space."
To learn more about The Gummy Project Inc. visit https://shopgummies.com
About The Gummy Project
The Gummy Project is a growing community of individuals and organizations who believe small contributions can add up to something big. The company sells low-sugar, plant-based gummy products while raising money (and awareness) to support endangered keystone species.  Gummy Project is the only "better for you" candy company that is built to support our planet's most precious species and ecosystems, while educating our future generations on the steps we must take today, to ensure a viable tomorrow.
About Stock Market Media Group
Stock Market Media Group is a news and media content development IR/PR firm offering a platform for corporate stories to unfold in the media with feature news articles, press releases, research reports, corporate videos, and radio-style CEO interviews. Your story, our words!
This article was written based on publicly available information. Stock Market Media Group may, from time to time, include our own opinions about the companies, their business, markets and opportunities in our articles. Any opinions we may offer about any of the companies we write about are solely our own and are made in reliance upon our rights under the First Amendment to the U.S. Constitution and are provided solely for the general opinionated discussion of our readers. Our opinions should not be considered to be complete, precise, accurate, or current investment advice, or construed or interpreted as research. Any investment decisions you may make concerning any of the securities we write about are solely your responsibility based on your own due diligence. Our publications are provided only as an informational aid, and as a starting point for doing additional independent research. We encourage you to invest carefully and read the investor information available at the web site of the U.S. Securities and Exchange Commission at www.sec.gov , where you can also find The Gummy Project's filings and disclosures. We also recommend, as a general rule, that before investing in any securities, you consult with a professional financial planner or advisor, and you should conduct a complete and independent investigation before investing in any security after prudent consideration of all pertinent risks.  We are not a registered broker, dealer, analyst, or advisor. We hold no investment licenses and may not sell, offer to sell, or offer to buy any security. Our publications about The Gummy Project are not a recommendation to buy or sell a security.
Should Stock Market Media Group and its management own shares in the profiled company, they may benefit from any increase in the share price of the profiled companies and hold the right to sell the shares bought at any given time including shortly after the release of the company's profile. Section 17(b) of the 1933 Securities and Exchange Act requires publishers who distribute information about publicly traded securities for compensation, to disclose who paid them, the amount, and the type of payment.  Under the Securities Act of 1933, Section 17(b), Stock Market Media Group discloses that it was remunerated one-thousand, three hundred dollars paid for by a third party via bank wire, to produce this content related to The Gummy Project.
Stock Market Media Group and its management do not own any shares in The Gummy Project and never accepts compensation in free-trading shares for its marketing services of the company being profiled, however third parties that have compensated Stock Market Media Group may hold free-trading shares of the company being profiled and could very well be selling, holding or buying shares of the company's stock at the same time the content is being disseminated to potential investors; this should be viewed as a definite conflict of interest and as such, the reader should take this into consideration.
If Stock Market Media Group ever accepts compensation in the form of free trading shares of the company being profiled and decides to sell these shares into the public market at any time before, during, or after the release of the company's profile, our disclaimer will be updated accordingly to reflect the current position of any free trading shares received as compensation for our services.
For more information: https://www.stockmarketmediagroup.com
Primary Logo
News Provided by GlobeNewswire via QuoteMedia

Investing News Network websites or approved third-party tools use cookies. Please refer to the  cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies. 

source

Posted in Blog
Write a comment
Contact Us
Phone
WhatsApp
WhatsApp
Phone
Contact Us